Acrivon Therapeutics
Business Services · Massachusetts, United States · 58 Employees
View Company Info for Free
About
Headquarters
480 Arsenal Way Ste 100, Watertown, Massachuset...Phone Number
(617) 207-8979Website
www.acrivon.comRevenue
$70.4 MillionStock Symbol
ACRVIndustry
Most Recent Scoops
Highlights
$100M
Total Funding Amount
$100M
Most Recent Funding Amount
1
Number of Funding Rounds
Who is Acrivon Therapeutics
Acrivon Therapeutics Org Chart
Is Acrivon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Acrivon Therapeutics
Product Launch: Get notified when Acrivon Therapeutics launches new products
Acrivon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Acrivon Therapeutics has new funding data
Earning: See what the market has to say on Acrivon Therapeutics recently announced quarterly report
Check out if Acrivon Therapeutics is spiking on competitors!
Click to see if Acrivon Therapeutics had a recent Job posting/layoffs
Check if Acrivon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Acrivon Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Acrivon Therapeutics
Compare insights from companies similar to Acrivon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Acrivon Therapeutics financials insights
Gather financial insights about Acrivon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Acrivon Therapeutics Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Acrivon Therapeutics Tech Stack
A closer look at the technologies used by Acrivon Therapeutics
Most Recent Scoops
Acrivon Therapeutics News & Media
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b endometrial cancer study presented at ESMOAcrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
WATERTOWN, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced the company will be presenting data on the ability of its AP3 platform tAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company approved a grant of equity awards under its 2023 InduceAcrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particula... Read More